NZS Capital’s Ginkgo Bioworks DNA Stock Holding History

NZS Capital’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-956	Closed	-$443K	–	70
2021 Q3	$443K	Buy	+956	New	+$465K	0.04%	67

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

SIG

Senator Investment Group New York $2.74B AUM 55.95% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

NZS Capital's DNA Position: Q4 2021 in Review

NZS Capital sold out of Ginkgo Bioworks (DNA) in Q4 2021, closing a stake of 956 shares — an estimated $443K sold.

NZS Capital first reported a position in DNA in Q3 2021 and held it in 1 quarter. The position peaked at $443K in Q3 2021. 164 funds tracked by Wall St. Rank hold DNA as of Q4 2021.

NZS Capital reported no remaining Ginkgo Bioworks position as of Q4 2021 after selling out during the quarter.
NZS Capital sold 956 Ginkgo Bioworks shares in Q4 2021, an estimated $443K.
NZS Capital first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 1 quarter.
NZS Capital's Ginkgo Bioworks position peaked at $443K in Q3 2021.
164 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2021.

Based on NZS Capital's 13F filing for Q4 2021, filed 14 Feb 2022.